Drug Database · Clinicians

Ertapenem

Brands (11) Carbexa, Ertabact, Ertaject…Show all

Antibacterial (carbapenem beta-lactam) PH FDA category

CrCl ≤30: 500 mg once dailyRx · Prescription drug11 PH productsPNF-listed Kidney dosing reviewed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 33f3b99b-fa82-42e0-26bf-f49891ae3d22, version date February 4, 2026 (INVANZ · Merck Sharp & Dohme LLC). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • INVANZ is a penem antibacterial indicated in adult patients and pediatric patients (3 months of age and older) for the treatment of the following moderate to severe infections caused by susceptible bacteria: Complicated…
  • Complicated skin and skin structure infections, including diabetic foot infections without osteomyelitis.
  • Community-acquired pneumonia.
  • Complicated urinary tract infections including pyelonephritis.
  • Acute pelvic infections including postpartum endomyometritis, septic abortion and post-surgical gynecologic infections.
  • INVANZ is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery.
  • To reduce the development of drug-resistant bacteria and maintain the effectiveness of INVANZ and other antibacterial drugs, INVANZ should be used only to treat or prevent infections that are proven or strongly…
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE INVANZ is a penem antibacterial indicated in adult patients and pediatric patients (3 months of age and older) for the treatment of the following moderate to severe infections caused by susceptible bacteria: Complicated intra-abdominal infections. (1.1) Complicated skin and skin structure infections, including diabetic foot infections without osteomyelitis.

(1.2) Community-acquired pneumonia. (1.3) Complicated urinary tract infections including pyelonephritis. (1.4) Acute pelvic infections including postpartum endomyometritis, septic abortion and post-surgical gynecologic infections. (1.5) INVANZ is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery.

(1.6) To reduce the development of drug-resistant bacteria and maintain the effectiveness of INVANZ and other antibacterial drugs, INVANZ should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. (1.7) 1.1 Complicated Intra-Abdominal Infections INVANZ is indicated for the treatment of adult patients and pediatric patients (3 months of age and older) with complicated intra-abdominal infections due to Escherichia coli, Clostridium clostridioforme, Eubacterium lentum, Peptostreptococcus species, Bacteroides fragilis, Bacteroides distasonis, Bacteroides ovatus, Bacteroides thetaiotaomicron, or Bacteroides uniformis. 1.2 Complicated Skin and Skin Structure Infections, Including Diabetic Foot Infections without Osteomyelitis INVANZ is indicated for the treatment of adult patients and pediatric patients (3 months of age and older) with complicated skin and skin structure infections, including diabetic foot infections without osteomyelitis due to Staphylococcus aureus (methicillin susceptible isolates only), Streptococcus agalactiae, Streptococcus pyogenes, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Bacteroides fragilis, Peptostreptococcus species, Porphyromonas asaccharolytica, or Prevotella bivia.

INVANZ has not been studied in diabetic foot infections with concomitant osteomyelitis [see Clinical Studies (14)]. 1.3 Community Acquired Pneumonia INVANZ is indicated for the treatment of adult patients and pediatric patients (3 months of age and older) with community acquired pneumonia due to Streptococcus pneumoniae (penicillin susceptible isolates only) including cases with concurrent bacteremia, Haemophilus influenzae (beta-lactamase negative isolates only), or Moraxella catarrhalis. 1.4 Complicated Urinary Tract Infections Including Pyelonephritis INVANZ is indicated for the treatment of adult patients and pediatric patients (3 months of age and older) with complicated urinary tract infections including pyelonephritis due to Escherichia coli, including cases with concurrent bacteremia, or Klebsiella pneumoniae. 1.5 Acute Pelvic Infections Including Postpartum Endomyometritis, Septic Abortion and Post-Surgical Gynecologic Infections INVANZ is indicated for the treatment of adult patients and pediatric patients (3 months of age and older) with acute pelvic infections including postpartum endomyometritis, septic abortion and post-surgical gynecological infections due to Streptococcus agalactiae, Escherichia coli, Bacteroides fragilis, Porphyromonas asaccharolytica, Peptostreptococcus species, or Prevotella bivia. 1.6 Prophylaxis of Surgical Site Infection Following Elective Colorectal Surgery INVANZ is indicated in adults for the prevention of surgical site infection following elective colorectal surgery. 1.7 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of INVANZ and other antibacterial drugs, INVANZ should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy.

In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Contraindications

  • Hypersensitivity to ertapenem or other carbapenems; anaphylaxis to beta-lactams
  • IM use: hypersensitivity to amide local anesthetics (lidocaine diluent)
renalcarematters.com, reviewed
Contraindications (US label) US FDA label

4 CONTRAINDICATIONS INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. Due to the use of lidocaine HCl as a diluent, INVANZ administered intramuscularly is contraindicated in patients with a known hypersensitivity to local anesthetics of the amide type.

Known hypersensitivity to product components or anaphylactic reactions to β-lactams. (4) Due to the use of lidocaine HCl as a diluent, INVANZ administered intramuscularly is contraindicated in patients with a known hypersensitivity to local anesthetics of the amide type. (4)

Dosing: Adult

  • Treatment (adults and 13 years and older): 1 g IV or IM once daily; IV up to 14 days, IM up to 7 days
  • Prophylaxis, elective colorectal surgery: 1 g IV once, 1 hour before incision
  • CrCl 30 mL/min/1.73 m2 or less: 500 mg once daily
renalcarematters.com, reviewed
Dosage and administration (US label) US FDA label
  • Do not mix or co-infuse INVANZ with other medications. Do not use diluents containing dextrose (α–D–glucose). (2.1)
  • INVANZ should be infused over 30 minutes in both the Treatment and Prophylactic regimens. (2.1)
  • Dosing considerations should be made in adults with advanced or end-stage renal impairment and those on hemodialysis. (2.4, 2.5)
  • Treatment regimen: Adults and pediatric patients 13 years of age and older. The dosage should be 1 gram once a day intravenously or intramuscularly. (2.2)
  • Patients 3 months to 12 years of age should be administered 15 mg/kg twice daily (not to exceed 1 g/day intravenously or intramuscularly). (2.2)
  • Intravenous infusion may be administered in adults and pediatrics for up to 14 days or intramuscular injection for up to 7 days. (2.1)
  • Prophylaxis regimen for adults: 1 gram single dose given 1 hour prior to elective colorectal surgery. (2.3)
2.1 Instructions for Use in All Patients For Intravenous or Intramuscular Use DO NOT MIX

2.1 Instructions for Use in All Patients For Intravenous or Intramuscular Use DO NOT MIX OR CO-INFUSE INVANZ WITH OTHER MEDICATIONS. DO NOT USE DILUENTS CONTAINING DEXTROSE (α-D-GLUCOSE). INVANZ may be administered by intravenous infusion for up to 14 days or intramuscular injection for up to 7 days. When administered intravenously, INVANZ should be infused over a period of 30 minutes.

Intramuscular administration of INVANZ may be used as an alternative to intravenous administration in the treatment of those infections for which intramuscular therapy is appropriate.

2.2 Treatment

2.2 Treatment Regimen 13 years of age and older The dose of INVANZ in patients 13 years of age and older is 1 gram (g) given once a day [see Clinical Pharmacology (12.3)]. 3 months to 12 years of age The dose of INVANZ in patients 3 months to 12 years of age is 15 mg/kg twice daily (not to exceed 1 g/day). Table 1 presents treatment guidelines for INVANZ.

Table 1 Treatment Guidelines for Adults and Pediatric Patients With Normal Renal Function defined as creatinine clearance >90 mL/min/1.73 m² and Body Weight Infection due to the designated pathogens [see Indications and Usage (1)] Daily Dose (IV or IM) Adults and Pediatric Patients 13 years of age and older Daily Dose (IV or IM) Pediatric Patients 3 months to 12 years of age Recommended Duration of Total Antimicrobial Treatment Complicated intra-abdominal infections 1 g 15 mg/kg twice daily not to exceed 1 g/day 5 to 14 days Complicated skin and skin structure infections, including diabetic foot infections INVANZ has not been studied in diabetic foot infections with concomitant osteomyelitis [see Clinical Studies (14.1)]. 1 g 15 mg/kg twice daily 7 to 14 days adult patients with diabetic foot infections received up to 28 days of treatment (parenteral or parenteral plus oral switch therapy) Community acquired pneumonia 1 g 15 mg/kg twice daily 10 to 14 days duration includes a possible switch to an appropriate oral therapy, after at least 3 days of parenteral therapy, once clinical improvement has been demonstrated. Complicated urinary tract infections, including pyelonephritis 1 g 15 mg/kg twice daily 10 to 14 days Acute pelvic infections including postpartum endomyometritis, septic abortion and post-surgical gynecologic infections 1 g 15 mg/kg twice daily 3 to 10 days

2.3 Prophylactic Regimen in Adults

2.3 Prophylactic Regimen in Adults Table 2 presents prophylaxis guidelines for INVANZ. Table 2 Prophylaxis Guidelines for Adults Indication Daily Dose (IV) Adults Recommended Duration of Total Antimicrobial Treatment Prophylaxis of surgical site infection following elective colorectal surgery 1 g Single intravenous dose given 1 hour prior to surgical incision

2.4 Patients with Renal Impairment

2.4 Patients with Renal Impairment INVANZ may be used for the treatment of infections in adult patients with renal impairment. In patients whose creatinine clearance is >30 mL/min/1.73 m², no dosage adjustment is necessary. Adult patients with severe renal impairment (creatinine clearance ≤30 mL/min/1.73 m²) and end-stage renal disease (creatinine clearance ≤10 mL/min/1.73 m²) should receive 500 mg daily.

A supplementary dose of 150 mg is recommended if ertapenem is administered within 6 hours prior to hemodialysis. There are no data in pediatric patients with renal impairment.

2.5 Patients on Hemodialysis

2.5 Patients on Hemodialysis When adult patients on hemodialysis are given the recommended daily dose of 500 mg of INVANZ within 6 hours prior to hemodialysis, a supplementary dose of 150 mg is recommended following the hemodialysis session. If INVANZ is given at least 6 hours prior to hemodialysis, no supplementary dose is needed.

There are no data in patients undergoing peritoneal dialysis or hemofiltration. There are no data in pediatric patients on hemodialysis. When only the serum creatinine is available, the following formula Cockcroft and Gault equation: Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976 may be used to estimate creatinine clearance.

The serum creatinine should represent a steady state of renal function. Males: (weight in kg) x (140-age in years) (72) x serum creatinine (mg/100 mL) Females: (0.85) x (value calculated for males)

2.6 Patients with Hepatic Impairment

2.6 Patients with Hepatic Impairment No dose adjustment recommendations can be made in patients with hepatic impairment [see Use in Specific Populations (8.7) and Clinical Pharmacology (12.3)].

2.7 Preparation and Reconstitution for Administration Vials

2.7 Preparation and Reconstitution for Administration Vials Adults and pediatric patients 13 years of age and older Preparation for intravenous administration: DO NOT MIX OR CO-INFUSE INVANZ WITH OTHER MEDICATIONS. DO NOT USE DILUENTS CONTAINING DEXTROSE (α-D-GLUCOSE). INVANZ MUST BE RECONSTITUTED AND THEN DILUTED PRIOR TO ADMINISTRATION.

Reconstitute the contents of a 1 g vial of INVANZ with 10 mL of one of the following: Water for Injection, 0.9% Sodium Chloride Injection or Bacteriostatic Water for Injection, using a syringe equipped with a 21-gauge or smaller diameter needle. NOTE: Use with a needleless IV system is not recommended. Shake well to dissolve and immediately transfer contents of the reconstituted vial to 50 mL of 0.9% Sodium Chloride Injection.

Complete the infusion within 6 hours of reconstitution. Preparation for intramuscular administration: INVANZ MUST BE RECONSTITUTED PRIOR TO ADMINISTRATION. Reconstitute the contents of a 1 g vial of INVANZ with 3.2 mL of 1.0% lidocaine HCl injection Refer to the prescribing information for lidocaine HCl. (without epinephrine).

Shake vial thoroughly to form solution. Immediately withdraw the contents of the vial and administer by deep intramuscular injection into a large muscle mass (such as the gluteal muscles or lateral part of the thigh). The reconstituted IM solution should be used within 1 hour after preparation. NOTE: THE RECONSTITUTED SOLUTION SHOULD NOT BE ADMINISTERED INTRAVENOUSLY.

Pediatric patients 3 months to 12 years of age Preparation for intravenous administration: DO NOT MIX OR CO-INFUSE INVANZ WITH OTHER MEDICATIONS. DO NOT USE DILUENTS CONTAINING DEXTROSE (α-D-GLUCOSE). INVANZ MUST BE RECONSTITUTED AND THEN DILUTED PRIOR TO ADMINISTRATION. Reconstitute the contents of a 1 g vial of INVANZ with 10 mL of one of the following: Water for Injection, 0.9% Sodium Chloride Injection or Bacteriostatic Water for Injection, using a syringe equipped with a 21-gauge or smaller diameter needle.

NOTE: Use with a needleless IV system is not recommended. Shake well to dissolve and immediately withdraw a volume equal to 15 mg/kg of body weight (not to exceed 1 g/day) and dilute in 0.9% Sodium Chloride Injection to a final concentration of 20 mg/mL or less. Discard vial with unused portion of INVANZ reconstituted solution.

Complete the infusion within 6 hours of reconstitution. Preparation for intramuscular administration: INVANZ MUST BE RECONSTITUTED PRIOR TO ADMINISTRATION. Reconstitute the contents of a 1 g vial of INVANZ with 3.2 mL of 1.0% lidocaine HCl injection (without epinephrine). Shake vial thoroughly to form solution. Immediately withdraw a volume equal to 15 mg/kg of body weight (not to exceed 1 g/day) and administer by deep intramuscular injection into a large muscle mass (such as the gluteal muscles or lateral part of the thigh).

Discard vial with unused portion of INVANZ reconstituted solution. The reconstituted IM solution should be used within 1 hour after preparation. NOTE: THE RECONSTITUTED SOLUTION SHOULD NOT BE ADMINISTERED INTRAVENOUSLY. Storage When prepared with the diluent, INVANZ (Ertapenem for Injection) maintains satisfactory potency for 6 hours at room temperature (25°C) or for 24 hours under refrigeration (5°C) and used within 4 hours after removal from refrigeration.

Solutions of INVANZ should not be frozen. Before administering, see accompanying package circular for INVANZ (Ertapenem for Injection). Parenteral drug products should be inspected visually for particulate matter and discoloration prior to use, whenever solution and container permit. Solutions of INVANZ range from colorless to pale yellow.

Variations of color within this range do not affect the potency of the product.

Dosing: Altered kidney function

Ertapenem is eliminated mainly by the kidneys (about 80% in urine, half as unchanged drug). The US label keeps 1 g once daily down to a creatinine clearance (CrCl) of 31 mL/min/1.73 m2 and gives 500 mg once daily at 30 or less, including end-stage kidney disease. On hemodialysis, a 150 mg supplement follows the session only if the daily dose was given within 6 hours before it.

Kidney function measure: Label uses CrCl in mL/min/1.73 m2 (Cockcroft–Gault formula quoted); cut-off 30. The mL/min/1.73 m2 unit is the label's own convention and is kept verbatim.

Show full dosing details
CrCl ≥60 mL/min/1.73 m2
No dose change (label: CrCl above 30 mL/min/1.73 m2): 1 g once daily.
CrCl 30–59 mL/min/1.73 m2
No dose change (label: CrCl above 30 mL/min/1.73 m2): 1 g once daily.
CrCl 15–29 mL/min/1.73 m2
CrCl 30 or less: 500 mg once daily (label).
CrCl <15 mL/min/1.73 m2 (not on dialysis)
500 mg once daily, including end-stage kidney disease (CrCl 10 or less) (label).
Hemodialysis (intermittent)
500 mg once daily. If the dose is given within 6 hours before hemodialysis, give 150 mg after the session; if given at least 6 hours before, no supplement (label). Literature option (not label): thrice-weekly after each session, 500 mg, 500 mg and 500 mg, or 1 g, 1 g and 1 g (evidence too limited to prefer one) (Tsai 2025). These regimens are not weight-adjusted and come mostly from small pharmacokinetic studies; confirm the actual last and next session before each dose. See the site guide Antibiotic Stewardship in Hemodialysis (/guides/antibiotic-stewardship-dialysis.html).
Peritoneal dialysis
No data in peritoneal dialysis (label). ISPD 2022 gives no intraperitoneal ertapenem dose. Specialist input.
CRRT
No hemofiltration data in label. Li 2020 (Table 3): CVVHD dialysate 1–3 L/h, or CVVHDF combined flow 36–51 mL/kg/h: 500 mg every 24 hours, 750 mg every 24 hours, 500 mg every 12 hours or 1,000 mg every 24 hours.
  • Dialyzable? Partly: about 30% of a 1 g dose was recovered in dialysate during a 4-hour hemodialysis started right after the dose (label). Highly protein bound (85% to 95%).
  • Monitoring CrCl for dose; seizures and other CNS effects, mainly with CNS disorders or reduced kidney function (label); valproate levels if coadministered.
Children (kidney dosing)
Show full dosing details
eGFR ≥60
Usual pediatric dose (label).
eGFR 30–59
No data in pediatric patients with kidney impairment or on hemodialysis (label). Specialist input.
eGFR 15–29
No data in pediatric patients with kidney impairment or on hemodialysis (label). Specialist input.
eGFR <15 (not on dialysis)
No data in pediatric patients with kidney impairment or on hemodialysis (label). Specialist input.
Hemodialysis (intermittent)
No data in pediatric patients with kidney impairment or on hemodialysis (label). Specialist input.
Peritoneal dialysis
No data in pediatric patients with kidney impairment or on hemodialysis (label). Specialist input.
CRRT
No data in pediatric patients with kidney impairment or on hemodialysis (label). Specialist input.

Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.

renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.

US label text: Renal impairment US FDA label

2.4 Patients with Renal Impairment INVANZ may be used for the treatment of infections in adult patients with renal impairment. In patients whose creatinine clearance is >30 mL/min/1.73 m², no dosage adjustment is necessary. Adult patients with severe renal impairment (creatinine clearance ≤30 mL/min/1.73 m²) and end-stage renal disease (creatinine clearance ≤10 mL/min/1.73 m²) should receive 500 mg daily. A supplementary dose of 150 mg is recommended if ertapenem is administered within 6 hours prior to hemodialysis. There are no data in pediatric patients with renal impairment.

2.5 Patients on Hemodialysis When adult patients on hemodialysis are given the recommended daily dose of 500 mg of INVANZ within 6 hours prior to hemodialysis, a supplementary dose of 150 mg is recommended following the hemodialysis session. If INVANZ is given at least 6 hours prior to hemodialysis, no supplementary dose is needed.

There are no data in patients undergoing peritoneal dialysis or hemofiltration. There are no data in pediatric patients on hemodialysis. When only the serum creatinine is available, the following formula Cockcroft and Gault equation: Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976 may be used to estimate creatinine clearance.

The serum creatinine should represent a steady state of renal function. Males: (weight in kg) x (140-age in years) (72) x serum creatinine (mg/100 mL) Females: (0.85) x (value calculated for males)

8.6 Patients with Renal Impairment Dosage adjustment is necessary in patients with creatinine clearance 30 mL/min or less [see Dosage and Administration (2.4) and Clinical Pharmacology (12.3)].

Renal Impairment Total and unbound fractions of ertapenem pharmacokinetics were investigated in 26 adult subjects (31 to 80 years of age) with varying degrees of renal impairment. Following a single 1 g IV dose of ertapenem, the unbound AUC increased 1.5-fold and 2.3-fold in subjects with mild renal impairment (CL CR 60-90 mL/min/1.73 m²) and moderate renal impairment (CL CR 31-59 mL/min/1.73 m²), respectively, compared with healthy young subjects (25 to 45 years of age).

No dosage adjustment is necessary in patients with CL CR ≥31 mL/min/1.73 m². The unbound AUC increased 4.4-fold and 7.6-fold in subjects with advanced renal impairment (CL CR 5-30 mL/min/1.73 m²) and end-stage renal disease (CL CR <10 mL/min/1.73 m²), respectively, compared with healthy young subjects. The effects of renal impairment on AUC of total drug were of smaller magnitude.

The recommended dose of ertapenem in adult patients with CL CR ≤30 mL/min/1.73 m² is 0.5 grams every 24 hours. Following a single 1 g IV dose given immediately prior to a 4 hour hemodialysis session in 5 adult patients with end-stage renal disease, approximately 30% of the dose was recovered in the dialysate. Dose adjustments are recommended for patients with severe renal impairment and end-stage renal disease [see Dosage and Administration (2.4)].

There are no data in pediatric patients with renal impairment.

Dosing: Hepatic impairment

8.7 Patients with Hepatic Impairment The pharmacokinetics of ertapenem in patients with hepatic impairment have not been established. Of the total number of patients in clinical trials, 37 patients receiving ertapenem 1 g daily and 36 patients receiving comparator drugs were considered to have Child-Pugh Class A, B, or C liver impairment. The incidence of adverse experiences in patients with hepatic impairment was similar between the ertapenem group and the comparator groups.

2.6 Patients with Hepatic Impairment No dose adjustment recommendations can be made in patients with hepatic impairment [see Use in Specific Populations (8.7) and Clinical Pharmacology (12.3)].

US FDA label

Dosing: Pediatric

Approved ages
3 months to 17 years; not recommended under 3 months (no data) or for meningitis (label).
Usual dose
3 months to 12 years: 15 mg/kg twice daily (maximum 1 g/day); 13 years and older: 1 g once daily (label).
Maximum dose
1 g/day (label).

Kidney dosing in children: see Dosing: Altered kidney function.

renalcarematters.com, reviewed
Pediatric use (US label) US FDA label

8.4 Pediatric Use Safety and effectiveness of INVANZ in pediatric patients 3 months to 17 years of age are supported by evidence from adequate and well-controlled trials in adults, pharmacokinetic data in pediatric patients, and additional data from comparator-controlled trials in pediatric patients 3 months to 17 years of age [see Indications and Usage (1.1), (1.2), (1.3), (1.4) and (1.5) and Clinical Studies (14.2)]. INVANZ is not recommended in infants under 3 months of age as no data are available.

INVANZ is not recommended in the treatment of meningitis in the pediatric population due to lack of sufficient CSF penetration.

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use Of the 1,835 patients in Phase 2b/3 trials treated with INVANZ, approximately 26 percent were 65 and over, while approximately 12 percent were 75 and over. No overall differences in safety or effectiveness were observed between these patients and younger patients. Other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function [see Dosage and Administration (2.2)].

Administration

2.1 Instructions for Use in All Patients For Intravenous or Intramuscular Use DO NOT MIX OR CO-INFUSE INVANZ WITH OTHER MEDICATIONS. DO NOT USE DILUENTS CONTAINING DEXTROSE (α-D-GLUCOSE). INVANZ may be administered by intravenous infusion for up to 14 days or intramuscular injection for up to 7 days. When administered intravenously, INVANZ should be infused over a period of 30 minutes. Intramuscular administration of INVANZ may be used as an alternative to intravenous administration in the treatment of those infections for which intramuscular therapy is appropriate.

2.7 Preparation and Reconstitution for Administration Vials Adults and pediatric patients 13 years of age and older Preparation for intravenous administration : DO NOT MIX OR CO-INFUSE INVANZ WITH OTHER MEDICATIONS. DO NOT USE DILUENTS CONTAINING DEXTROSE (α-D-GLUCOSE). INVANZ MUST BE RECONSTITUTED AND THEN DILUTED PRIOR TO ADMINISTRATION. Reconstitute the contents of a 1 g vial of INVANZ with 10 mL of one of the following: Water for Injection, 0.9% Sodium Chloride Injection or Bacteriostatic Water for Injection, using a syringe equipped with a 21-gauge or smaller diameter needle. NOTE: Use with a needleless IV system is not recommended. Shake well to dissolve and immediately transfer contents of the reconstituted vial to 50 mL of 0.9% Sodium Chloride Injection. Complete the infusion within 6 hours of reconstitution. Preparation for intramuscular administration: INVANZ MUST BE RECONSTITUTED PRIOR TO ADMINISTRATION. Reconstitute the contents of a 1 g vial of INVANZ with 3.2 mL of 1.0% lidocaine HCl injection Refer to the prescribing information for lidocaine HCl. ( without epinephrine ). Shake vial thoroughly to form solution. Immediately withdraw the contents of the vial and administer by deep intramuscular injection into a large muscle mass (such as the gluteal muscles or lateral part of the thigh). The reconstituted IM solution should be used within 1 hour after preparation. NOTE: THE RECONSTITUTED SOLUTION SHOULD NOT BE ADMINISTERED INTRAVENOUSLY . Pediatric patients 3 months to 12 years of age Preparation for intravenous administration: DO NOT MIX OR CO-INFUSE INVANZ WITH OTHER MEDICATIONS. DO NOT USE DILUENTS CONTAINING DEXTROSE (α-D-GLUCOSE). INVANZ MUST BE RECONSTITUTED AND THEN DILUTED PRIOR TO ADMINISTRATION. Reconstitute the contents of a 1 g vial of INVANZ with 10 mL of one of the following: Water for Injection, 0.9% Sodium Chloride Injection or Bacteriostatic Water for Injection, using a syringe equipped with a 21-gauge or smaller diameter needle. NOTE: Use with a needleless IV system is not recommended. Shake well to dissolve and immediately withdraw a volume equal to 15 mg/kg of body weight (not to exceed 1 g/day) and dilute in 0.9% Sodium Chloride Injection to a final concentration of 20 mg/mL or less. Discard vial with unused portion of INVANZ reconstituted solution. Complete the infusion within 6 hours of reconstitution. Preparation for intramuscular administration: INVANZ MUST BE RECONSTITUTED PRIOR TO ADMINISTRATION. Reconstitute the contents of a 1 g vial of INVANZ with 3.2 mL of 1.0% lidocaine HCl injection ( without epinephrine ). Shake vial thoroughly to form solution. Immediately withdraw a volume equal to 15 mg/kg of body weight (not to exceed 1 g/day) and administer by deep intramuscular injection into a large muscle mass (such as the gluteal muscles or lateral part of the thigh). Discard vial with unused portion of INVANZ reconstituted solution. The reconstituted IM solution should be used within 1 hour after preparation. NOTE: THE RECONSTITUTED SOLUTION SHOULD NOT BE ADMINISTERED INTRAVENOUSLY . Storage When prepared with the diluent, INVANZ (Ertapenem for Injection) maintains satisfactory potency for 6 hours at room temperature (25°C) or for 24 hours under refrigeration (5°C) and used within 4 hours after removal from refrigeration. Solutions of INVANZ should not be frozen . Before administering, see accompanying package circular for INVANZ (Ertapenem for Injection). Parenteral drug products should be inspected visually for particulate matter and discoloration prior to use, whenever solution and container permit. Solutions of INVANZ range from colorless to pale yellow. Variations of color within this range do not affect the potency of the product.

US FDA label

Dosage forms

Philippines

  • Lyophilized powder for injection: 1 g
  • Powder for injection: 1 g
  • Lyophilized injection: 1 g
  • Lyophilized powder: 1 g
  • Lyophilized powder for solution for injection: 1 g
  • Lyophilized powder powder for injection: 1 g

Registered products in the Philippines

11 products registered with the Food and Drug Administration (FDA) Philippines list Ertapenem as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products11
Philippine FDA-registered products for Ertapenem
Package insert
CarbexaErtapenem (as Sodium)
1 g Lyophilized Powder For Solution for Injection (IM/IV)20 mL-capacity type I clear glass vial with rubber stopper and aluminum plastic cap (Box of 1's and 10's)
Rx
Qilu Antibiotics Pharmaceutical Co., Ltd.China
Nextgen Pharmaceuticals Inc.
DRP-18116
May 6, 2031
ErtabactErtapenem (as sodium)
1 g Powder for Injection (I.M/I.V.)USP Type I clear glass vial, with grey bromobutyl rubber stopper, aluminum seal and flip-off cap x 5 mL- capacity clear glass ampoule of Sterile Water for Injection x 2.5 mL-net content (as diluent); (Box of 1 finished product and 1 diluent)
Rx
Friends Pharma (Pvt.) Ltd.Pakistan
Raquel-Abbas Pharmaceuticals & General Merchandise
DRP-17508
Jan 19, 2032
ErtajectErtapenem (as sodium)
1 g Lyophilized Powder Powder for Injection (I.M./I.V. Infusion)Type 1 neutral borosilicate glass vial with rubber stopper and sealed with an aluminum-plastic flip cap (Box of 1's)
Rx
CSPC Ouyi Pharmaceutical Co. Ltd.China
AMB HK Enterprises Inc.
DRP-14400
Sep 5, 2028
ErtalymErtapenem (as sodium)
1 g Lyophilized Powder for Injection (I.M./I.V.)USP Type I Glass Vial with Grey Bromo Butyl Rubber Stopper and Aluminum Flip-off Seal (Box of 1's)
Rx
Lyka Labs LimitedIndia
Ambica International Corporation
DRP-6735
Jun 22, 2031
ErtapErtapenem (as sodium)
1 g Lyophilized Powder (I.M./I.V. )20 mL Type I glass vials with a grey bromo butyl rubber stopper and a blue coloured aluminium flip-off seal.
Rx
Brooks Steriscience LimitedIndia
Biocare Lifesciences, Inc.
DRP-17888
Apr 28, 2032
ErtapenErtapenem (As Sodium)
1g Lyophilized Powder for Injection (I.V./I.M.)20 mL Type I clear glass vial with grey halobutyl rubber stopper and aluminium-plastic flip off cap x l's (Box of 10's)
Rx
Savior Lifetec Corporation (Tainan Branch Injection Plant)Taiwan
Endure Medical, Inc.
DR-XY48122
Oct 4, 2027
ErtapenexErtapenem (as sodium)
1 g Lyophilized Powder for Injection (I.M./I.V.)20 mL USP Type I clear moulded glass vial with 20 mm grey butyl rubber stopper sealed with with 20 mm transparent pink flip-off seal individually packed in mono carton (Box of 5's).
Rx
United Biotech Pvt. Ltd.India
Delex Pharma International, Inc.
DRP-17589
Feb 5, 2031
ErtaxErtapenem (as sodium)
1g Lyophilized Powder for Injection (I.M./I.V. Infusion)Type 1 neutral borosilicate glass vial with rubber stopper and sealed with an aluminum-plastic flip cap (Box of 1's)
Rx
CSPC Ouyi Pharmaceutical Co., Ltd.China
Innogen Pharmaceuticals, Inc.Importer: AMB HK Enterprises Inc.
DRP-14400-01
Sep 5, 2028
ErtunoxErtapenem
1 g Lyophilized Injection (I.M./I.V.)USP Type I clear tubular glass vial with chorobutyl rubber plugs and gray button aluminum flip off seals x 20 mL (Box of 1’s)
Rx
Gland Pharma LimitedIndia
Camber Pharmaceuticals, Inc.
DRP-18787
Sep 7, 2031
InvanzErtapenem (as sodium)
1 g Powder for Injection (I.M./I.V.)15 mL USP Type I Flint Tubing Vial with Gray Butyl Stopper and Aluminum Seal and Flip-top Cap
Rx
FAREVA MirabelFrance
Importer: Merck Sharp & Dohme (I.A.) LLC
DRP-4619
Jul 4, 2027
One-ErtaErtapenem (as sodium)
1 g Lyophilized Powder for Injection (I.M./I.V.)USP Type I clear glass vial x 20 mL (net content) with grey bromobutyl rubber stopper, aluminum seal and blue flip-off cap (Box of 1’s)
Rx
Brooks Steriscience LimitedIndia
One Dexcel Pharma Inc.
DRP-18310
Jun 17, 2032

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS For Injection: Vials INVANZ is a sterile lyophilized powder in a single-dose vial containing 1 g ertapenem equivalent to 1.046 g ertapenem sodium for intravenous infusion or for intramuscular injection after reconstitution. For injection: Single-dose vial 1 gram. (3)

Warnings/Precautions

Warnings and precautions (US label) US FDA label
  • Serious hypersensitivity (anaphylactic) reactions have been reported in patients receiving β-lactams. (5.1)
  • Seizures and other central nervous system adverse experiences have been reported during treatment. (5.2)
  • Co-administration of INVANZ with valproic acid or divalproex sodium reduces the serum concentration of valproic acid potentially increasing the risk of breakthrough seizures. (5.3)
  • Clostridioides difficile -associated diarrhea (ranging from mild diarrhea to fatal colitis): Evaluate if diarrhea occurs. (5.4)
  • Caution should be taken when administering INVANZ intramuscularly to avoid inadvertent injection into a blood vessel. (5.5)
5.1 Hypersensitivity Reactions

5.1 Hypersensitivity Reactions Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving therapy with beta-lactams. These reactions are more likely to occur in individuals with a history of sensitivity to multiple allergens. There have been reports of individuals with a history of penicillin hypersensitivity who have experienced severe hypersensitivity reactions when treated with another beta-lactam.

Before initiating therapy with INVANZ, careful inquiry should be made concerning previous hypersensitivity reactions to penicillins, cephalosporins, other beta-lactams and other allergens. If an allergic reaction to INVANZ occurs, discontinue the drug immediately. Serious anaphylactic reactions require immediate emergency treatment as clinically indicated.

5.2 Seizure Potential

5.2 Seizure Potential Seizures and other central nervous system (CNS) adverse experiences have been reported during treatment with INVANZ [see Adverse Reactions (6.1)]. During clinical investigations in adult patients treated with INVANZ (1 g once a day), seizures, irrespective of drug relationship, occurred in 0.5% of patients during study therapy plus 14-day follow-up period [see Adverse Reactions (6.1)].

These experiences have occurred most commonly in patients with CNS disorders (e.g., brain lesions or history of seizures) and/or compromised renal function. Close adherence to the recommended dosage regimen is urged, especially in patients with known factors that predispose to convulsive activity. Anticonvulsant therapy should be continued in patients with known seizure disorders.

If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued.

5.3 Interaction with Valproic Acid

5.3 Interaction with Valproic Acid Case reports in the literature have shown that co-administration of carbapenems, including ertapenem, to patients receiving valproic acid or divalproex sodium results in a reduction in valproic acid concentrations. The valproic acid concentrations may drop below the therapeutic range as a result of this interaction, therefore increasing the risk of breakthrough seizures.

Increasing the dose of valproic acid or divalproex sodium may not be sufficient to overcome this interaction. The concomitant use of ertapenem and valproic acid/divalproex sodium is generally not recommended. Anti-bacterials other than carbapenems should be considered to treat infections in patients whose seizures are well controlled on valproic acid or divalproex sodium.

If administration of INVANZ is necessary, supplemental anti-convulsant therapy should be considered [see Drug Interactions (7.2)].

5.4 Clostridioides difficile- Associated Diarrhea (CDAD)

5.4 Clostridioides difficile- Associated Diarrhea (CDAD) CDAD has been reported with use of nearly all antibacterial agents, including ertapenem, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of Clostridioides difficile.

Clostridioides difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of Clostridioides difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use.

Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against Clostridioides difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of Clostridioides difficile, and surgical evaluation should be instituted as clinically indicated.

5.5 Caution with Intramuscular Administration

5.5 Caution with Intramuscular Administration Caution should be taken when administering INVANZ intramuscularly to avoid inadvertent injection into a blood vessel [see Dosage and Administration (2.7)].

5.6 Development of Drug-Resistant Bacteria

5.6 Development of Drug-Resistant Bacteria As with other antibiotics, prolonged use of INVANZ may result in overgrowth of non-susceptible organisms. Repeated evaluation of the patient's condition is essential. If superinfection occurs during therapy, appropriate measures should be taken. Prescribing INVANZ in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

5.7 Laboratory Tests While

5.7 Laboratory Tests While INVANZ possesses toxicity similar to the beta-lactam group of antibiotics, periodic assessment of organ system function, including renal, hepatic, and hematopoietic, is advisable during prolonged therapy.

Drug interactions

Drug or classSeverityEffectWhat to do
ProbenecidAvoidBlocks tubular secretion; higher and longer drug levels (label).Coadministration not recommended.
Valproic acid or divalproexAvoidCarbapenems lower valproate levels below the therapeutic range; breakthrough seizures (label).Generally not recommended; prefer a non-carbapenem.

Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.

renalcarematters.com, reviewed
Drug interactions (US label) US FDA label
  • Co-administration with probenecid inhibits the renal excretion of ertapenem and is therefore not recommended. (7.1)
  • The concomitant use of ertapenem and valproic acid/divalproex sodium is generally not recommended. Anti-bacterials other than carbapenems should be considered to treat infections in patients whose seizures are well controlled on valproic acid or divalproex sodium. (5.2, 7.2)
7.1 Probenecid

7.1 Probenecid Probenecid interferes with the active tubular secretion of ertapenem, resulting in increased plasma concentrations of ertapenem [see Clinical Pharmacology (12.3)]. Co-administration of probenecid with ertapenem is not recommended.

7.2 Valproic Acid

7.2 Valproic Acid Case reports in the literature have shown that co-administration of carbapenems, including ertapenem, to patients receiving valproic acid or divalproex sodium results in a reduction of valproic acid concentrations. The valproic acid concentrations may drop below the therapeutic range as a result of this interaction, therefore increasing the risk of breakthrough seizures.

Although the mechanism of this interaction is unknown, data from in vitro and animal studies suggest that carbapenems may inhibit the hydrolysis of valproic acid's glucuronide metabolite (VPA-g) back to valproic acid, thus decreasing the serum concentrations of valproic acid [see Warnings and Precautions (5.3)].

Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label

In vitro studies indicate that ertapenem does not inhibit P-glycoprotein-mediated transport of digoxin or vinblastine and that ertapenem is not a substrate for P-glycoprotein-mediated transport.

Adverse reactions

Common

  • Diarrhea, nausea, headache
  • Infused vein complications

Serious

  • Anaphylaxis
  • Seizures and other CNS effects
  • Clostridioides difficile-associated diarrhea
renalcarematters.com, reviewed
Adverse reactions (US label) US FDA label
  • The following are described in greater detail in the Warnings and Precautions section. Hypersensitivity Reactions [see Warnings and Precautions (5.1)] Seizure Potential [see Warnings and Precautions (5.2)] Interaction with Valproic Acid [see Warnings and Precautions (5.3)] Clostridioides difficile -Associated Diarrhea (CDAD) [see Warnings and Precautions (5.4)] Caution with Intramuscular Administration [see Warnings and Precautions (5.5)] Development of Drug-Resistant Bacteria [see Warnings and Precautions (5.6)] Laboratory Tests [see Warnings and Precautions (5.7)] Adults: The most common adverse reactions (≥5%) in patients treated with INVANZ, including those who were switched to therapy with an oral antimicrobial, were diarrhea, nausea, headache and infused vein complication. (6.1)
  • In the prophylaxis indication the overall adverse experience profile was generally comparable to that observed for ertapenem in other clinical trials. (6.1)
  • Pediatrics: Adverse reactions in this population were comparable to adults. The most common adverse reactions (≥5%) in pediatric patients treated with INVANZ, including those who were switched to therapy with an oral antimicrobial, were diarrhea, vomiting and infusion site pain. (6.1)
  • To report SUSPECTED ADVERSE REACTIONS, contact Merck Sharp & Dohme LLC at 1-877-888-4231 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience

6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Adults Receiving INVANZ as a Treatment Regimen Clinical trials enrolled 1954 patients treated with INVANZ; in some of the clinical trials, parenteral therapy was followed by a switch to an appropriate oral antimicrobial [see Clinical Studies (14)].

Most adverse experiences reported in these clinical trials were described as mild to moderate in severity. INVANZ was discontinued due to adverse experiences in 4.7% of patients. Table 3 shows the incidence of adverse experiences reported in ≥2.0% of patients in these trials. The most common drug-related adverse experiences in patients treated with INVANZ, including those who were switched to therapy with an oral antimicrobial, were diarrhea (5.5%), infused vein complication (3.7%), nausea (3.1%), headache (2.2%), and vaginitis in females (2.1%).

Table 3 Incidence (%) of Adverse Experiences Reported During Study Therapy Plus 14-Day Follow-Up in ≥2.0% of Adult Patients Treated With INVANZ in Clinical Trials INVANZ Includes Phase IIb/III Complicated intra-abdominal infections, Complicated skin and skin structure infections and Acute pelvic infections trials 1 g daily Piperacillin/ Tazobactam 3.375 g q6h INVANZ Includes Phase IIb/III Community acquired pneumonia and Complicated urinary tract infections, and Phase IIa trials 1 g daily Ceftriaxone 1 or 2 g daily Adverse Events (N=802) (N=774) (N=1152) (N=942) Local: Infused vein complication 7.1 7.9 5.4

6.7 Systemic

6.7 Systemic: Death 2.5 1.6 1.3 1.6 Edema/swelling 3.4 2.5 2.9 3.3 Fever 5.0 6.6 2.3 3.4 Abdominal pain 3.6 4.8 4.3 3.9 Hypotension 2.0 1.4 1.0 1.2 Constipation 4.0 5.4 3.3 3.1 Diarrhea 10.3 12.1 9.2 9.8 Nausea 8.5 8.7 6.4 7.4 Vomiting 3.7 5.3 4.0 4.0 Altered mental status Includes agitation, confusion, disorientation, decreased mental acuity, changed mental status, somnolence, stupor 5.1 3.4 3.3 2.5 Dizziness 2.1 3.0 1.5 2.1 Headache 5.6 5.4 6.8

6.9 Insomnia 3

6.9 Insomnia 3.2 5.2 3.0 4.1 Dyspnea 2.6 1.8 1.0 2.4 Pruritus 2.0 2.6 1.0 1.9 Rash 2.5 3.1 2.3 1.5 Vaginitis 1.4 1.0 3.3 3.7 In patients treated for complicated intra-abdominal infections, death occurred in 4.7% (15/316) of patients receiving INVANZ and 2.6% (8/307) of patients receiving comparator drug. These deaths occurred in patients with significant co-morbidity and/or severe baseline infections.

Deaths were considered unrelated to study drugs by investigators. In clinical trials, seizure was reported during study therapy plus 14-day follow-up period in 0.5% of patients treated with INVANZ, 0.3% of patients treated with piperacillin/tazobactam and 0% of patients treated with ceftriaxone [see Warnings and Precautions (5.2)].

Additional adverse experiences that were reported with INVANZ with an incidence >0.1% within each body system are listed below Body as a Whole: abdominal distention, pain, chills, septicemia, septic shock, dehydration, gout, malaise, asthenia/fatigue, necrosis, candidiasis, weight loss, facial edema, injection site induration, injection site pain, extravasation, phlebitis/thrombophlebitis, flank pain, syncope Cardiovascular System: heart failure, hematoma, chest pain, hypertension, tachycardia, cardiac arrest, bradycardia, arrhythmia, atrial fibrillation, heart murmur, ventricular tachycardia, asystole, subdural hemorrhage Digestive System: acid regurgitation, oral candidiasis, dyspepsia, gastrointestinal hemorrhage, anorexia, flatulence, C. difficile -associated diarrhea, stomatitis, dysphagia, hemorrhoids, ileus, cholelithiasis, duodenitis, esophagitis, gastritis, jaundice, mouth ulcer, pancreatitis, pyloric stenosis Musculoskeletal System: leg pain Nervous System & Psychiatric: anxiety, nervousness, seizure [see Warnings and Precautions (5.2)], tremor, depression, hypesthesia, spasm, paresthesia, aggressive behavior, vertigo Respiratory System: cough, pharyngitis, rales/rhonchi, respiratory distress, pleural effusion, hypoxemia, bronchoconstriction, pharyngeal discomfort, epistaxis, pleuritic pain, asthma, hemoptysis, hiccups, voice disturbance Skin & Skin Appendage: erythema, sweating, dermatitis, desquamation, flushing, urticaria Special Senses: taste perversion Urogenital System: renal impairment, oliguria/anuria, vaginal pruritus, hematuria, urinary retention, bladder dysfunction, vaginal candidiasis, vulvovaginitis. In a clinical trial for the treatment of diabetic foot infections in which 289 adult diabetic patients were treated with INVANZ, the adverse experience profile was generally similar to that seen in previous clinical trials.

Prophylaxis of Surgical Site Infection following Elective Colorectal Surgery In a clinical trial in adults for the prophylaxis of surgical site infection following elective colorectal surgery in which 476 patients received a 1 g dose of INVANZ 1 hour prior to surgery and were then followed for safety 14 days post-surgery, the overall adverse experience profile was generally comparable to that observed for INVANZ in previous clinical trials. Table 4 shows the incidence of adverse experiences other than those previously described above for INVANZ that were reported regardless of causality in ≥2.0% of patients in this trial.

Table 4 Incidence (%) of Adverse Experiences Reported During Study Therapy Plus 14-Day Follow-Up in ≥2.0% of Adult Patients Treated With INVANZ for Prophylaxis of Surgical Site Infections Following Elective Colorectal Surgery Adverse Events INVANZ 1 g (N = 476) Cefotetan 2 g (N = 476) Anemia 5.7

6.9 Small

6.9 Small intestinal obstruction 2.1 1.9 Pneumonia 2.1 4.0 Postoperative infection 2.3 4.0 Urinary tract infection 3.8 5.5 Wound infection 6.5 12.4 Wound complication 2.9 2.3 Atelectasis 3.4 1.9 Additional adverse experiences that were reported in this prophylaxis trial with INVANZ, regardless of causality, with an incidence >0.5% within each body system are listed below: Gastrointestinal Disorders: C. difficile infection or colitis, dry mouth, hematochezia General Disorders and Administration Site Condition: crepitations Infections and Infestations: cellulitis, abdominal abscess, fungal rash, pelvic abscess Injury, Poisoning and Procedural Complications: incision site complication, incision site hemorrhage, intestinal stoma complication, anastomotic leak, seroma, wound dehiscence, wound secretion Musculoskeletal and Connective Tissue Disorders: muscle spasms Nervous System Disorders: cerebrovascular accident Renal and Urinary Disorders: dysuria, pollakiuria Respiratory, Thoracic and Mediastinal Disorders: crackles lung, lung infiltration, pulmonary congestion, pulmonary embolism, wheezing. Pediatric Patients Receiving INVANZ as a Treatment Regimen Clinical trials enrolled 384 patients treated with INVANZ; in some of the clinical trials, parenteral therapy was followed by a switch to an appropriate oral antimicrobial [see Clinical Studies (14)].

The overall adverse experience profile in pediatric patients is comparable to that in adult patients. Table 5 shows the incidence of adverse experiences reported in ≥2.0% of pediatric patients in clinical trials. The most common drug-related adverse experiences in pediatric patients treated with INVANZ, including those who were switched to therapy with an oral antimicrobial, were diarrhea (6.5%), infusion site pain (5.5%), infusion site erythema (2.6%), vomiting (2.1%).

Table 5 Incidence (%) of Adverse Experiences Reported During Study Therapy Plus 14-Day Follow-Up in ≥2.0% of Pediatric Patients Treated With INVANZ in Clinical Trials INVANZ Includes Phase IIb Complicated skin and skin structure infections, Community acquired pneumonia and Complicated urinary tract infections trials in which patients 3 months to 12 years of age received INVANZ 15 mg/kg IV twice daily up to a maximum of 1 g or ceftriaxone 50 mg/kg/day IV in two divided doses up to a maximum of 2 g, and patients 13 to 17 years of age received INVANZ 1 g IV daily or ceftriaxone 50 mg/kg/day IV in a single daily dose., Includes Phase IIb Acute pelvic infections and Complicated intra-abdominal infections trials in which patients 3 months to 12 years of age received INVANZ 15 mg/kg IV twice daily up to a maximum of 1 g and patients 13 to 17 years of age received INVANZ 1 g IV daily or ticarcillin/clavulanate 50 mg/kg for patients <60 kg or ticarcillin/clavulanate 3.0 g for patients >60 kg, 4 or 6 times a day. Ceftriaxone Ticarcillin/ Clavulanate Adverse Events (N=384) (N=100) (N=24) Local: Infusion Site Erythema 3.9 3.0 8.3 Infusion Site Pain 7.0 4.0 20.8 Systemic: Abdominal Pain 4.7 3.0 4.2 Constipation 2.3 0.0 0.0 Diarrhea 11.7 17.0 4.2 Loose Stools 2.1 0.0 0.0 Vomiting 10.2 11.0 8.3 Pyrexia 4.9 6.0 8.3 Upper Respiratory Tract Infection 2.3 3.0 0.0 Headache 4.4 4.0 0.0 Cough 4.4 3.0 0.0 Diaper Dermatitis 4.7 4.0 0.0 Rash 2.9 2.0 8.3 Additional adverse experiences that were reported with INVANZ with an incidence >0.5% within each body system are listed below: Gastrointestinal Disorders: nausea General Disorders and Administration Site Condition: hypothermia, chest pain, upper abdominal pain; infusion site pruritus, induration, phlebitis, swelling, and warmth Infections and Infestations: candidiasis, oral candidiasis, viral pharyngitis, herpes simplex, ear infection, abdominal abscess Metabolism and Nutrition Disorders: decreased appetite Musculoskeletal and Connective Tissue Disorders: arthralgia Nervous System Disorders: dizziness, somnolence Psychiatric Disorders: insomnia Reproductive System and Breast Disorders: genital rash Respiratory, Thoracic and Mediastinal Disorders: wheezing, nasopharyngitis, pleural effusion, rhinitis, rhinorrhea Skin and Subcutaneous Tissue Disorders: dermatitis, pruritus, rash erythematous, skin lesion Vascular Disorders: phlebitis.

6.2 Post-Marketing Experience

6.2 Post-Marketing Experience The following additional adverse reactions have been identified during the post-approval use of INVANZ. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Gastrointestinal Disorders: teeth staining Immune System Disorders: anaphylaxis including anaphylactoid reactions Musculoskeletal and Connective Tissue Disorders: muscular weakness Nervous System Disorders: coordination abnormal, depressed level of consciousness, dyskinesia, gait disturbance, myoclonus, tremor, encephalopathy (recovery was prolonged in patients with renal impairment) Psychiatric Disorders: altered mental status (including aggression, delirium), hallucinations Skin and Subcutaneous Tissue Disorders: Acute Generalized Exanthematous Pustulosis (AGEP), Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS syndrome), hypersensitivity vasculitis

6.3 Adverse Laboratory Changes in Clinical Trials Adults Receiving

6.3 Adverse Laboratory Changes in Clinical Trials Adults Receiving INVANZ as Treatment Regimen Laboratory adverse experiences that were reported during therapy in ≥2.0% of adult patients treated with INVANZ in clinical trials are presented in Table 6. Drug-related laboratory adverse experiences that were reported during therapy in ≥2.0% of adult patients treated with INVANZ, including those who were switched to therapy with an oral antimicrobial, in clinical trials were ALT increased (6.0%), AST increased (5.2%), serum alkaline phosphatase increased (3.4%), and platelet count increased (2.8%).

INVANZ was discontinued due to laboratory adverse experiences in 0.3% of patients. Table 6 Incidence Number of patients with laboratory adverse experiences/Number of patients with the laboratory test (%) of Laboratory Adverse Experiences Reported During Study Therapy Plus 14-Day Follow-Up in ≥2.0% of Adult Patients Treated With INVANZ in Clinical Trials INVANZ Includes Phase IIb/III Complicated intra-abdominal infections, Complicated skin and skin structure infections and Acute pelvic infections trials 1 g daily Piperacillin/ Tazobactam 3.375 g q6h INVANZ Includes Phase IIb/III Community acquired pneumonia and Complicated urinary tract infections, and Phase IIa trials 1 g daily Ceftriaxone 1 or 2 g daily Adverse laboratory experiences (n Number of patients with one or more laboratory tests =766) (n =755) (n =1122) (n =920) ALT increased 8.8 7.3 8.3

6.9 AST

6.9 AST increased 8.4 8.3 7.1

6.5 Serum

6.5 Serum alkaline phosphatase increased 6.6 7.2 4.3 2.8 Eosinophils increased 1.1 1.1 2.1 1.8 Hematocrit decreased 3.0 2.9 3.4 2.4 Hemoglobin decreased 4.9 4.7 4.5 3.5 Platelet count increased 6.5 6.3 4.3 3.5 Urine RBCs increased 2.5 2.9 1.1 1.0 Urine WBCs increased 2.5 3.2 1.6 1.1 Additional laboratory adverse experiences that were reported during therapy in >0.1% of patients treated with INVANZ in clinical trials include: increases in serum creatinine, serum glucose, BUN, total, direct and indirect serum bilirubin, serum sodium and potassium, PT and PTT; decreases in serum potassium, serum albumin, WBC, platelet count, and segmented neutrophils. In a clinical trial for the treatment of diabetic foot infections in which 289 adult diabetic patients were treated with INVANZ, the laboratory adverse experience profile was generally similar to that seen in previous clinical trials.

Prophylaxis of Surgical Site Infection following Elective Colorectal Surgery In a clinical trial in adults for the prophylaxis of surgical site infection following elective colorectal surgery in which 476 patients received a 1 g dose of INVANZ 1 hour prior to surgery and were then followed for safety 14 days post-surgery, the overall laboratory adverse experience profile was generally comparable to that observed for INVANZ in previous clinical trials. Pediatric Patients Receiving INVANZ as a Treatment Regimen Laboratory adverse experiences that were reported during therapy in ≥2.0% of pediatric patients treated with INVANZ in clinical trials are presented in Table 7.

Drug-related laboratory adverse experiences that were reported during therapy in ≥2.0% of pediatric patients treated with INVANZ, including those who were switched to therapy with an oral antimicrobial, in clinical trials were neutrophil count decreased (3.0%), ALT increased (2.2%), and AST increased (2.1%). Table 7 Incidence Number of patients with laboratory adverse experiences/Number of patients with the laboratory test; where at least 300 patients had the test (%) of Specific Laboratory Adverse Experiences Reported During Study Therapy Plus 14-Day Follow-Up in ≥2.0% of Pediatric Patients Treated With INVANZ in Clinical Trials INVANZ Ceftriaxone Ticarcillin/ Clavulanate Adverse laboratory experiences (n Number of patients with one or more laboratory tests =379) (n =97) (n =24) ALT Increased 3.8 1.1 4.3 AST Increased 3.8 1.1 4.3 Neutrophil Count Decreased 5.8 3.1 0.0 Additional laboratory adverse experiences that were reported during therapy in >0.5% of patients treated with INVANZ in clinical trials include: alkaline phosphatase increased, eosinophil count increased, platelet count increased, white blood cell count decreased and urine protein present.

Adverse reaction frequency tables (US label) US FDA label
Table 3 Incidence (%) of Adverse Experiences Reported During Study Therapy Plus 14-Day Follow-Up in ≥2.0% of Adult Patients Treated With INVANZ in Clinical Trials
INVANZIncludes Phase IIb/III Complicated intra-abdominal infections, Complicated skin and skin structure infections and Acute pelvic infections trials 1 g dailyPiperacillin/ Tazobactam 3.375 g q6hINVANZIncludes Phase IIb/III Community acquired pneumonia and Complicated urinary tract infections, and Phase IIa trials 1 g dailyCeftriaxone 1 or 2 g daily
Adverse Events(N=802)(N=774) (N=1152)(N=942)
Local:
Infused vein complication 7.17.95.46.7
Systemic:
Death 2.51.61.31.6
Edema/swelling 3.42.52.93.3
Fever 5.06.62.33.4
Abdominal pain3.64.84.33.9
Hypotension 2.01.41.01.2
Constipation 4.05.43.33.1
Diarrhea 10.312.19.29.8
Nausea 8.58.76.47.4
Vomiting 3.75.34.04.0
Altered mental status Includes agitation, confusion, disorientation, decreased mental acuity, changed mental status, somnolence, stupor5.13.43.32.5
Dizziness 2.13.01.52.1
Headache 5.65.46.86.9
Insomnia 3.25.23.04.1
Dyspnea 2.61.81.02.4
Pruritus 2.02.61.01.9
Rash 2.53.12.31.5
Vaginitis1.41.03.33.7
Table 4 Incidence (%) of Adverse Experiences Reported During Study Therapy Plus 14-Day Follow-Up in ≥2.0% of Adult Patients Treated With INVANZ for Prophylaxis of Surgical Site Infections Following Elective Colorectal Surgery
Adverse EventsINVANZ 1 g (N = 476) Cefotetan 2 g (N = 476)
Anemia5.76.9
Small intestinal obstruction2.11.9
Pneumonia2.14.0
Postoperative infection2.34.0
Urinary tract infection3.85.5
Wound infection6.512.4
Wound complication2.92.3
Atelectasis3.41.9
Table 5 Incidence (%) of Adverse Experiences Reported During Study Therapy Plus 14-Day Follow-Up in ≥2.0% of Pediatric Patients Treated With INVANZ in Clinical Trials
INVANZIncludes Phase IIb Complicated skin and skin structure infections, Community acquired pneumonia and Complicated urinary tract infections trials in which patients 3 months to 12 years of age received INVANZ 15 mg/kg IV twice daily up to a maximum of 1 g or ceftriaxone 50 mg/kg/day IV in two divided doses up to a maximum of 2 g, and patients 13 to 17 years of age received INVANZ 1 g IV daily or ceftriaxone 50 mg/kg/day IV in a single daily dose.,Includes Phase IIb Acute pelvic infections and Complicated intra-abdominal infections trials in which patients 3 months to 12 years of age received INVANZ 15 mg/kg IV twice daily up to a maximum of 1 g and patients 13 to 17 years of age received INVANZ 1 g IV daily or ticarcillin/clavulanate 50 mg/kg for patients <60 kg or ticarcillin/clavulanate 3.0 g for patients >60 kg, 4 or 6 times a day.CeftriaxoneTicarcillin/ Clavulanate
Adverse Events (N=384)(N=100)(N=24)
Local:
Infusion Site Erythema3.93.08.3
Infusion Site Pain7.04.020.8
Systemic:
Abdominal Pain4.73.04.2
Constipation2.30.00.0
Diarrhea11.717.04.2
Loose Stools2.10.00.0
Vomiting10.211.08.3
Pyrexia4.96.08.3
Upper Respiratory Tract Infection2.33.00.0
Headache4.44.00.0
Cough4.43.00.0
Diaper Dermatitis 4.74.00.0
Rash2.92.08.3
Table 6 IncidenceNumber of patients with laboratory adverse experiences/Number of patients with the laboratory test (%) of Laboratory Adverse Experiences Reported During Study Therapy Plus 14-Day Follow-Up in ≥2.0% of Adult Patients Treated With INVANZ in Clinical Trials
INVANZIncludes Phase IIb/III Complicated intra-abdominal infections, Complicated skin and skin structure infections and Acute pelvic infections trials 1 g dailyPiperacillin/ Tazobactam 3.375 g q6hINVANZIncludes Phase IIb/III Community acquired pneumonia and Complicated urinary tract infections, and Phase IIa trials 1 g dailyCeftriaxone 1 or 2 g daily
Adverse laboratory experiences(nNumber of patients with one or more laboratory tests=766)(n=755)(n=1122)(n=920)
ALT increased 8.87.38.36.9
AST increased 8.48.37.16.5
Serum alkaline phosphatase increased 6.67.24.32.8
Eosinophils increased 1.11.12.11.8
Hematocrit decreased 3.02.93.42.4
Hemoglobin decreased 4.94.74.53.5
Platelet count increased 6.56.34.33.5
Urine RBCs increased 2.52.91.11.0
Urine WBCs increased 2.53.21.61.1
Table 7 IncidenceNumber of patients with laboratory adverse experiences/Number of patients with the laboratory test; where at least 300 patients had the test (%) of Specific Laboratory Adverse Experiences Reported During Study Therapy Plus 14-Day Follow-Up in ≥2.0% of Pediatric Patients Treated With INVANZ in Clinical Trials
INVANZCeftriaxoneTicarcillin/ Clavulanate
Adverse laboratory experiences(nNumber of patients with one or more laboratory tests=379) (n=97)(n=24)
ALT Increased3.81.14.3
AST Increased3.81.14.3
Neutrophil Count Decreased5.83.10.0

Monitoring parameters

  • CrCl for dose; seizures and other CNS effects, mainly with CNS disorders or reduced kidney function (label); valproate levels if coadministered. Kidney
  • CrCl for dose
  • Seizure risk with CNS disease or kidney impairment
  • Valproate levels if coadministered
renalcarematters.com, reviewed

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Risk Summary Available data from a small number of post-marketing cases with INVANZ use in pregnancy are insufficient to inform any drug-associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes. In animal reproduction studies after intravenous administration of ertapenem during the period of organogenesis, there was no evidence of developmental malformations in rats at systemic exposures (AUC) up to approximately 1.2 times the human exposure at the maximum recommended human dose (MRHD) and in mice at doses up to approximately 3 times the MRHD based on body surface area comparison.

In pregnant rats administered ertapenem during organogenesis through lactation, fetal toxicity, developmental delays, and impaired reproduction did not occur in first generation offspring at systemic exposures (AUC) approximately 1.2 times the human exposure at the MRHD (see Data). The estimated background risk of major birth defects and miscarriage for the indicated population is unknown.

All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Animal Data In pregnant rats, intravenous administration of ertapenem dosages of up to 700 mg/kg/day (approximately 1.2 times the MRHD based on AUC) during the period of organogenesis (gestation days [GD] 6-20) revealed no maternal or embryofetal effects.

Pregnant mice intravenously administered ertapenem dosages of up to 700 mg/kg/day (approximately 3 times the MRHD based on body surface area comparison) during the period of organogenesis (GD 6-15) showed slight decreases in average fetal weight and an associated decrease in the average number of ossified sacrocaudal vertebrae. There were no maternal effects at any dosage.

In a pre-postnatal study in rats, ertapenem administered to pregnant rats at dosages up to 700 mg/kg/day (approximately 1.2 times the MRHD based on AUC) during organogenesis through lactation, (GD 6 until Lactation Day (LD) 20) did not result in fetal toxicity, developmental delays, or impaired reproduction in first generation offspring, and fetal deaths and malformations were not increased in second generation offspring.

Mechanism of action

12.1 Mechanism of Action Ertapenem sodium is a carbapenem antibiotic [see Clinical Pharmacology (12.4)].

US FDA label

Pharmacokinetics

Key PK parameters

BioavailabilityIM about 90%
Time to peakIM: about 2.3 hours
Half-lifeAbout 4 hours
Half-life in kidney failure (ESKD) kidneyUnbound AUC 7.6 times normal in end-stage kidney disease (label; no half-life given)
Volume of distributionAbout 0.12 L/kg
Protein bindingAbout 85% to 95% (falls as concentration rises)
Metabolism (CYP, transporters)Hydrolysis to an inactive ring-opened metabolite
Active metabolitesNone
Renal excretion kidneyAbout 80% in urine (38% unchanged, 37% metabolite); 10% in feces
Dialyzability kidneyPartly (about 30% of a dose in a 4-hour session)
renalcarematters.com, reviewed
Half-life and elimination (verbatim, US label)

The mean plasma half-life in healthy young adults is approximately 4 hours and the plasma clearance is approximately 1.8 L/hour.

The mean plasma half-life in pediatric patients 13 to 17 years of age is approximately 4 hours and approximately 2.5 hours in pediatric patients 3 months to 12 years of age.

Of the 80% recovered in urine, approximately 38% is excreted as unchanged drug and approximately 37% as the ring-opened metabolite.

In healthy young adults given a 1 g IV dose, the mean percentage of the administered dose excreted in urine was 17.4% during 0-2 hours postdose, 5.4% during 4-6 hours postdose, and 2.4% during 12-24 hours postdose.

Drug Interactions When ertapenem is co-administered with probenecid (500 mg p.o. every 6 hours), probenecid competes for active tubular secretion and reduces the renal clearance of ertapenem.

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics Average plasma concentrations (mcg/mL) of ertapenem following a single 30-minute infusion of a 1 g intravenous (IV) dose and administration of a single 1 g intramuscular (IM) dose in healthy young adults are presented in Table 8. Table 8 Plasma Concentrations of Ertapenem in Adults After Single Dose Administration Average Plasma Concentrations (mcg/mL) Dose/Route 0.5 hr 1 hr 2 hr 4 hr 6 hr 8 hr 12 hr 18 hr 24 hr 1 g IV Infused at a constant rate over 30 minutes 155 115 83 48 31 20 9 3 1 1 g IM 33 53 67 57 40 27 13 4 2 The area under the plasma concentration-time curve (AUC) of ertapenem in adults increased less-than dose-proportional based on total ertapenem concentrations over the 0.5 to 2 g dose range, whereas the AUC increased greater-than dose-proportional based on unbound ertapenem concentrations.

Ertapenem exhibits non-linear pharmacokinetics due to concentration-dependent plasma protein binding at the proposed therapeutic dose [see Clinical Pharmacology (12.3)]. There is no accumulation of ertapenem following multiple IV or IM 1 g daily doses in healthy adults. Average plasma concentrations (mcg/mL) of ertapenem in pediatric patients are presented in Table 9.

Table 9 Plasma Concentrations of Ertapenem in Pediatric Patients After Single IV Infused at a constant rate over 30 minutes Dose Administration Age Group Dose Average Plasma Concentrations (mcg/mL) 0.5 hr 1 hr 2 hr 4 hr 6 hr 8 hr 12 hr 24 hr 3 to 23 months 15 mg/kg up to a maximum dose of 1 g/day 103.8 57.3 43.6 23.7 13.5 8.2 2.5 - 20 mg/kg 126.8 87.6 58.7 28.4 - 12.0 3.4 0.4 40 mg/kg up to a maximum dose of 2 g/day 199.1 144.1 95.7 58.0 - 20.2 7.7 0.6 2 to 12 years 15 mg/kg 113.2 63.9 42.1 21.9 12.8 7.6 3.0 - 20 mg/kg 147.6 97.6 63.2 34.5 - 12.3 4.9 0.5 40 mg/kg 241.7 152.7 96.3 55.6 - 18.8 7.2 0.6 13 to 17 years 20 mg/kg 170.4 98.3 67.8 40.4 - 16.0 7.0 1.1 1 g Based on three patients receiving 1 g ertapenem who volunteered for pharmacokinetic assessment in one of the two safety and efficacy trials 155.9 110.9 74.8 - 24.0 - 6.2 - 40 mg/kg 255.0 188.7 127.9 76.2 - 31.0 15.3 2.1 Absorption Ertapenem, reconstituted with 1% lidocaine HCl injection, USP (in saline without epinephrine), is almost completely absorbed following intramuscular (IM) administration at the recommended dose of 1 g. The mean bioavailability is approximately 90%.

Following 1 g daily IM administration, mean peak plasma concentrations (C max) are achieved in approximately 2.3 hours (T max). Distribution Ertapenem is highly bound to human plasma proteins, primarily albumin. In healthy young adults, the protein binding of ertapenem decreases as plasma concentrations increase, from approximately 95% bound at an approximate plasma concentration of <100 micrograms (mcg)/mL to approximately 85% bound at an approximate plasma concentration of 300 mcg/mL.

The apparent volume of distribution at steady state (V ss) of ertapenem in adults is approximately 0.12 liter/kg, approximately 0.2 liter/kg in pediatric patients 3 months to 12 years of age and approximately 0.16 liter/kg in pediatric patients 13 to 17 years of age. The concentrations of ertapenem achieved in suction-induced skin blister fluid at each sampling point on the third day of 1 g once daily IV doses are presented in Table 10.

The ratio of AUC 0-24 in skin blister fluid/AUC 0-24 in plasma is 0.61. Table 10 Concentrations (mcg/mL) of Ertapenem in Adult Skin Blister Fluid at each Sampling Point on the Third Day of 1-g Once Daily IV Doses 0.5 hr 1 hr 2 hr 4 hr 8 hr 12 hr 24 hr 7 12 17 24 24 21 8 Metabolism In healthy young adults, after infusion of 1 g IV radiolabeled ertapenem, the plasma radioactivity consists predominantly (94%) of ertapenem.

The major metabolite of ertapenem is the inactive ring-opened derivative formed by hydrolysis of the beta-lactam ring. Elimination Ertapenem is eliminated primarily by the kidneys. The mean plasma half-life in healthy young adults is approximately 4 hours and the plasma clearance is approximately 1.8 L/hour. The mean plasma half-life in pediatric patients 13 to 17 years of age is approximately 4 hours and approximately 2.5 hours in pediatric patients 3 months to 12 years of age.

Following the administration of 1 g IV radiolabeled ertapenem to healthy young adults, approximately 80% is recovered in urine and 10% in feces. Of the 80% recovered in urine, approximately 38% is excreted as unchanged drug and approximately 37% as the ring-opened metabolite. In healthy young adults given a 1 g IV dose, the mean percentage of the administered dose excreted in urine was 17.4% during 0-2 hours postdose, 5.4% during 4-6 hours postdose, and 2.4% during 12-24 hours postdose.

Special Populations Renal Impairment Total and unbound fractions of ertapenem pharmacokinetics were investigated in 26 adult subjects (31 to 80 years of age) with varying degrees of renal impairment. Following a single 1 g IV dose of ertapenem, the unbound AUC increased 1.5-fold and 2.3-fold in subjects with mild renal impairment (CL CR 60-90 mL/min/1.73 m²) and moderate renal impairment (CL CR 31-59 mL/min/1.73 m²), respectively, compared with healthy young subjects (25 to 45 years of age).

No dosage adjustment is necessary in patients with CL CR ≥31 mL/min/1.73 m². The unbound AUC increased 4.4-fold and 7.6-fold in subjects with advanced renal impairment (CL CR 5-30 mL/min/1.73 m²) and end-stage renal disease (CL CR <10 mL/min/1.73 m²), respectively, compared with healthy young subjects. The effects of renal impairment on AUC of total drug were of smaller magnitude.

The recommended dose of ertapenem in adult patients with CL CR ≤30 mL/min/1.73 m² is 0.5 grams every 24 hours. Following a single 1 g IV dose given immediately prior to a 4 hour hemodialysis session in 5 adult patients with end-stage renal disease, approximately 30% of the dose was recovered in the dialysate. Dose adjustments are recommended for patients with severe renal impairment and end-stage renal disease [see Dosage and Administration (2.4)].

There are no data in pediatric patients with renal impairment. Hepatic Impairment The pharmacokinetics of ertapenem in patients with hepatic impairment have not been established. However, ertapenem does not appear to undergo hepatic metabolism based on in vitro studies and approximately 10% of an administered dose is recovered in the feces [see Clinical Pharmacology (12.3) and Dosage and Administration (2.6)].

Gender The effect of gender on the pharmacokinetics of ertapenem was evaluated in healthy male (n=8) and healthy female (n=8) subjects. The differences observed could be attributed to body size when body weight was taken into consideration. No dose adjustment is recommended based on gender. Geriatric Patients The impact of age on the pharmacokinetics of ertapenem was evaluated in healthy male (n=7) and healthy female (n=7) subjects ≥65 years of age.

The total and unbound AUC increased 37% and 67%, respectively, in elderly adults relative to young adults. These changes were attributed to age-related changes in creatinine clearance. No dosage adjustment is necessary for elderly patients with normal (for their age) renal function. Pediatric Patients Plasma concentrations of ertapenem are comparable in pediatric patients 13 to 17 years of age and adults following a 1 g once daily IV dose.

Following the 20 mg/kg dose (up to a maximum dose of 1 g), the pharmacokinetic parameter values in patients 13 to 17 years of age (N=6) were generally comparable to those in healthy young adults. Plasma concentrations at the midpoint of the dosing interval following a single 15 mg/kg IV dose of ertapenem in patients 3 months to 12 years of age are comparable to plasma concentrations at the midpoint of the dosing interval following a 1 g once daily IV dose in adults [see Clinical Pharmacology (12.3)].

The plasma clearance (mL/min/kg) of ertapenem in patients 3 months to 12 years of age is approximately 2-fold higher as compared to that in adults. At the 15 mg/kg dose, the AUC value (doubled to model a twice daily dosing regimen, i.e., 30 mg/kg/day exposure) in patients 3 months to 12 years of age was comparable to the AUC value in young healthy adults receiving a 1 g IV dose of ertapenem.

Drug Interactions When ertapenem is co-administered with probenecid (500 mg p.o. every 6 hours), probenecid competes for active tubular secretion and reduces the renal clearance of ertapenem. Based on total ertapenem concentrations, probenecid increased the AUC of ertapenem by 25%, and reduced the plasma and renal clearance of ertapenem by 20% and 35%, respectively.

The half-life of ertapenem was increased from 4.0 to 4.8 hours. In vitro studies in human liver microsomes indicate that ertapenem does not inhibit metabolism mediated by any of the following cytochrome p450 (CYP) isoforms: 1A2, 2C9, 2C19, 2D6, 2E1 and 3A4. In vitro studies indicate that ertapenem does not inhibit P-glycoprotein-mediated transport of digoxin or vinblastine and that ertapenem is not a substrate for P-glycoprotein-mediated transport.

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Ertapenem (as Sodium) 1 g Vial₱2,562.57–₱3,016.02Reference ₱2,562.57per vialDPRI procurement range

Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Ertapenem (as sodium salt)
PNF listingInj.: 1 g powder, vial (IM/IV)Restrictions: Reserve antimicrobial (PNF)
PhilHealth GAMOTNo

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. INVANZ · Merck Sharp & Dohme LLC [US FDA-approved label, version 42, February 4, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=33f3b99b-fa82-42e0-26bf-f49891ae3d22
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
  5. Merck Sharp & Dohme LLC. (2026). INVANZ (ertapenem) for injection [Prescribing information; US FDA-approved label, NDA021337, set ID 33f3b99b-fa82-42e0-26bf-f49891ae3d22, version effective February 4, 2026]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=33f3b99b-fa82-42e0-26bf-f49891ae3d22
  6. Li, L., Li, X., Xia, Y., Chu, Y., Zhong, H., Li, J., Liang, P., Bu, Y., Zhao, R., Liao, Y., Yang, P., Lu, X., & Jiang, S. (2020). Recommendation of antimicrobial dosing optimization during continuous renal replacement therapy. Frontiers in Pharmacology, 11, Article 786. https://doi.org/10.3389/fphar.2020.00786
  7. Tsai, Y. V., Soto, C., Crawford, G., & Dzintars, K. (2025). Important antimicrobial dosing considerations for transitions of care: Focus on thrice-weekly dosing in hemodialysis. American Journal of Health-System Pharmacy, 82(4), 203–210. https://doi.org/10.1093/ajhp/zxae259

renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .